US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
SDEV
$7.48
▲+0.00%
WDC
$415.29
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
SDEV
$7.48
▲+0.00%
WDC
$415.29
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Denali Therapeutics Inc. - Common Stock
(NQ:
DNLI
)
20.00
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Denali Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine
September 30, 2026
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:BIOA),(NASDAQ:GERN),(NASDAQ:DNLI) EQNX::TICKER_END
Via
FinancialNewsMedia
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
AVLAYAH revenue hit $3.6M in first full quarter post-approval.
Via
The Motley Fool
Topics
Earnings
Denali Therapeutics (NASDAQ:DNLI) Shows Perfect Technical Setup for a Breakout
↗
August 12, 2026
Via
Chartmill
Denali Therapeutics Q2 Earnings Call Highlights
↗
August 06, 2026
Denali Therapeutics (NASDAQ:DNLI) reported $3.6 million in net product revenue from AVLAYAH during the second quarter of 2026, its first full quarter of commercial availability, as the company expanded...
Via
MarketBeat
Topics
Earnings
Denali Therapeutics (NASDAQ:DNLI) Drops as Q2 AVLAYAH Revenue Misses Estimates
↗
August 06, 2026
Via
Chartmill
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
August 06, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
July 27, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
July 09, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
June 18, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
May 21, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
↗
May 18, 2026
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.
Via
The Motley Fool
Topics
Regulatory Compliance
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
↗
May 16, 2026
Denali Therapeutics (NASDAQ:DNLI) is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24 accelerated approval for Hunter syndrome, Chief Operating Officer and...
Via
MarketBeat
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
May 07, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval
↗
May 05, 2026
This biotech company develops therapies for neurodegenerative and rare diseases, supported by clinical assets and pharma collaborations.
Via
The Motley Fool
Topics
Regulatory Compliance
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
April 20, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
April 20, 2026
From
BioMedWire
Via
GlobeNewswire
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
April 03, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
April 02, 2026
In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug...
Via
MarketMinute
Topics
Intellectual Property
Lawsuit
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
March 26, 2026
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)...
Via
Finterra
Topics
Economy
Initial Public Offering
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
March 25, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 26, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
February 19, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
February 19, 2026
From
BioMedWire
Via
GlobeNewswire
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
February 06, 2026
Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,...
Via
MarketMinute
Topics
Intellectual Property
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
February 05, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
February 02, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
January 29, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
January 06, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
December 30, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More
↗
December 10, 2025
Via
The Motley Fool
< Previous
1
2
3
4
5
6
Next >
